Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 3,146.5% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 80,222 shares of the biopharmaceutical company's stock after purchasing an additional 77,751 shares during the quarter. GAMMA Investing LLC's holdings in Royalty Pharma were worth $2,577,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after purchasing an additional 130,025 shares during the period. Jupiter Asset Management Ltd. purchased a new stake in shares of Royalty Pharma during the 4th quarter worth about $4,950,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Royalty Pharma by 303.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock worth $13,926,000 after purchasing an additional 406,123 shares during the period. Truist Financial Corp purchased a new stake in shares of Royalty Pharma during the 4th quarter worth about $371,000. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Royalty Pharma during the 4th quarter worth about $230,000. Hedge funds and other institutional investors own 54.35% of the company's stock.

Analyst Ratings Changes

RPRX has been the topic of several recent research reports. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Morgan Stanley initiated coverage on Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 price target on the stock. Finally, Wall Street Zen lowered Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma currently has a consensus rating of "Buy" and a consensus target price of $47.33.

Royalty Pharma Stock Up 0.7%

Royalty Pharma stock traded up $0.26 during midday trading on Monday, hitting $35.10. 3,618,986 shares of the company were exchanged, compared to its average volume of 3,610,915. The company's fifty day moving average price is $32.90 and its 200-day moving average price is $31.04. The company has a market cap of $19.73 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 2.31 and a beta of 0.48. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $35.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. On average, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date was Friday, May 16th. Royalty Pharma's payout ratio is 47.57%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.